Why Are Innovative Drugs Failing in Phase III?

被引：15

作者：

Marder, Stephen R. ^{[1
]}

Laughren, Thomas

Romano, Steven J. ^{[2
]}

机构：

[1] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA

[2] Mallinckrodt Pharmaceut, St Louis, MO USA

来源：

AMERICAN JOURNAL OF PSYCHIATRY | 2017年 / 174卷 / 09期

关键词：

CLINICAL-TRIALS; DISORDERS;

D O I：

10.1176/appi.ajp.2017.17040426

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

页码：829 / 831

页数：3

共 7 条

[1] The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach [J].

Fava, M ;

Evins, AE ;

Dorer, DJ ;

Schoenfeld, DA .

PSYCHOTHERAPY AND PSYCHOSOMATICS, 2003, 72 (03) :115-127

[2] Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD [J].

Papakostas, George I. ;

Fava, Maurizio .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (01) :34-40

[3] Mitigating the Effects of Nonadherence in Clinical Trials [J].

Shiovitz, Thomas M. ;

Bain, Earle E. ;

McCann, David J. ;

Skolnick, Phil ;

Laughren, Thomas ;

Hanina, Adam ;

Burch, Daniel .

JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (09) :1151-1164

[4] Redefining affective disorders: Relevance for drug development [J].

Targum, Steven D. ;

Pollack, Mark H. ;

Fava, Maurizio .

CNS NEUROSCIENCE & THERAPEUTICS, 2008, 14 (01) :2-9

[5] DOES A PLACEBO RUN-IN OR A PLACEBO-TREATMENT CELL AFFECT THE EFFICACY OF ANTIDEPRESSANT MEDICATIONS [J].

TRIVEDI, MH ;

RUSH, J .

NEUROPSYCHOPHARMACOLOGY, 1994, 11 (01) :33-43

[6] Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review [J].

Undurraga, Juan ;

Baldessarini, Ross J. .

NEUROPSYCHOPHARMACOLOGY, 2012, 37 (04) :851-864

[7] Factors modifying drug and placebo responses in randomized trials for bipolar mania [J].

Yildiz, Aysegul ;

Vieta, Eduard ;

Tohen, Mauricio ;

Baldessarini, Ross J. .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2011, 14 (07) :863-875

← 1 →